person · Reporting owner
Niklas Victoria Ninon Olivia
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FibroBiologics, Inc.FBLG · Entity 7875 | Director | June 23, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FibroBiologics, Inc.
Report date June 23, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2036-06-22 | Direct | 30,803 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 30,803 · Balance 30,803 F1: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 23, 2026 23:59 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 30,803 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001493152-26-029848 · ownership.xml · derivative · entry 1 Niklas Victoria Ninon Olivia · CIK 0002012250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,803 Underlying: Common Stock · 30,803 shares Expires 2036-06-22 F1 · derivative.exercise_date: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 23:30 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001641172-25-014941 · ownership.xml · derivative · entry 1 Niklas Victoria Ninon Olivia · CIK 0002012250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2025-06-11 F1 · derivative.exercise_date: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. Read SEC document |
| August 27, 2024 Filed Aug 27, 2024 23:55 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001493152-24-034072 · ownership.xml · derivative · entry 1 Niklas Victoria Ninon Olivia · CIK 0002012250 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.